Since its founding in 2021, the company has built the world's largest proprietary, clinical-grade dataset on the vaginal microbiome and women's health outcomes - and the machine learning engine, EvvyAI, that interprets large-scale biological data to transform patient care. This round will fund the validation of a new generation of AI-driven diagnostic and care models across women's health, starting with fertility.

The Series B funding round includes new investors Catalio Capital Management, Rethink Impact, Muse Capital, and Alumni Ventures, alongside existing investors LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures.

Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy's groundbreaking Vaginal Health Test is the world's only CLIA-certified, CLEP-approved mNGS test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways, Evvy provides 100,000+ patients with data-driven, personalized care for vaginal infections, fertility, menopause, and more. Evvy is backed by 15+ peer-reviewed publications & abstracts, including validation of their novel test methodology and a study demonstrating significant improvements to patient outcomes. Evvy has built the world's largest dataset on the vaginal microbiome and is pioneering research to improve outcomes across the female lifespan.